Viking Therapeutics Inc (VKTX)

[DMOST]

Little vktx, and with that I will be disengaging........[

SAN DIEGO, June 7, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its public offering of 7,500,000 shares of its common stock at a price to the public of $9.00 per share. Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $67.5 million. Viking currently intends to use the net proceeds from the offering for continued development of its VK2809, VK5211 and VK0214 programs and for general research and development, working capital and general corporate purposes. In addition, Viking has granted the underwriters a 30-day option to purchase up to 1,125,000 additional shares of its common stock. The offering is expected to close on or about June 11, 2018, subject to satisfaction of customary closing conditions.

"peace"